Isolated oculomotor nerve palsy as a paraneoplastic manifestation of gastric diffuse large B‑cell lymphoma: A case report

Yan,Shang‑Yih; Peng,Yi‑Jen; Lin,Chun–Shu; Peng,Giia‑Sheun; Chang,Ping‑Ying

doi:10.3892/ol.2014.2454

Isolated oculomotor nerve palsy as a paraneoplastic manifestation of gastric diffuse large B‑cell lymphoma: A case report

Authors:
- Shang‑Yih Yan
- Yi‑Jen Peng
- Chun–Shu Lin
- Giia‑Sheun Peng
- Ping‑Ying Chang
View Affiliations

Affiliations: Department of Neurology, Tri‑Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan, R.O.C., Department of Pathology, Tri‑Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan, R.O.C., Department of Radiation Oncology, Tri‑Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan, R.O.C., Division of Hematology/Oncology, Department of Internal Medicine, Tri‑Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan, R.O.C.
Published online on: August 19, 2014 https://doi.org/10.3892/ol.2014.2454
Pages: 1983-1985

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Isolated oculomotor nerve palsy (ONP) is rare. The major causes are aneurysm of the posterior communicating artery, microvascular ischemia, neoplasm, inflammation and trauma. The present study reports the case of a 72‑year‑old female with left isolated pupil‑sparing ONP and severe anemia as the initial manifestations of gastric diffuse large B‑cell lymphoma (DLBCL). Systemic chemotherapy without any central nervous system (CNS)‑directed treatment led to a complete resolution of the ONP, suggesting that it was most likely to be a paraneoplastic phenomenon. If CNS involvement cannot be demonstrated by brain magnetic resonance imaging and cerebrospinal fluid assessment, the present case suggests that it may be acceptable to omit CNS‑directed therapy in such cases of ONP, since it may be paraneoplastic in nature and may resolve following successful treatment of the underlying malignancy.

View Figures

View References

1	d’Amore F, Brincker H, Grønbaek K, et al: Non-Hodgkin’s lymphoma of the gastrointestinal tract: a population-based analysis of incidence, geographic distribution, clinicopathologic presentation features, and prognosis. Danish Lymphoma Study Group. J Clin Oncol. 12:1673–1684. 1994.
2	Psyrri A, Papageorgiou S and Economopoulos T: Primary extranodal lymphomas of stomach: clinical presentation, diagnostic pitfalls and management. Ann Oncol. 19:1992–1999. 2008.
3	Coiffier B and Salles G: Does surgery belong to medical history for gastric lymphomas? Ann Oncol. 8:419–421. 1997.
4	Raderer M, Chott A, Drach J, et al: Chemotherapy for management of localised high-grade gastric B-cell lymphoma: how much is necessary? Ann Oncol. 13:1094–1098. 2002.
5	Tanaka T, Shimada K, Yamamoto K, et al: Retrospective analysis of primary gastric diffuse large B cell lymphoma in the rituximab era: a multicenter study of 95 patients in Japan. Ann Hematol. 91:383–390. 2012.
6	Zhang J, Li G, Yang H, Liu X and Cao J: Rituximab in treatment of primary gastric diffuse large B-cell lymphoma. Leuk Lymphoma. 53:2175–2181. 2012.
7	Hughes RA, Britton T and Richards M: Effects of lymphoma on the peripheral nervous system. J R Soc Med. 87:526–530. 1994.
8	Recht LD: Neurologic complications of systemic lymphoma. Neurol Clin. 9:1001–1015. 1991.
9	Law IP, Dick FR, Blom J and Bergevin PR: Involvement of the central nervous system in non-Hodgkin’s lymphoma. Cancer. 36:225–231. 1975.
10	Levitt LJ, Dawson DM, Rosenthal DS and Moloney WC: CNS involvement in the non-Hodgkin’s lymphomas. Cancer. 45:545–552. 1980.
11	MacKintosh FR, Colby TV, Podolsky WJ, et al: Central nervous system involvement in non-Hodgkin’s lymphoma: an analysis of 105 cases. Cancer. 49:586–595. 1982.
12	Woodruff MM and Edlow JA: Evaluation of third nerve palsy in the emergency department. J Emerg Med. 35:239–246. 2008.
13	Bruce BB, Biousse V and Newman NJ: Third nerve palsies. Semin Neurol. 27:257–268. 2007.
14	Feugier P, Virion JM, Tilly H, et al: Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Ann Oncol. 15:129–133. 2004.
15	Kumar A, Vanderplas A, LaCasce AS, et al: Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database. Cancer. 118:2944–2951. 2012.
16	Tomita N, Yokoyama M, Yamamoto W, et al: Central nervous system event in patients with diffuse large B-cell lymphoma in the rituximab era. Cancer Sci. 103:245–251. 2012.
17	van Besien K, Gisselbrecht C, Pfreundschuh M and Zucca E: Secondary lymphomas of the central nervous system: risk, prophylaxis and treatment. Leuk Lymphoma. 49:52–58. 2008.
18	Kim SJ, Oh SY, Kim JS, et al: Secondary central nervous system (CNS) involvement in patients with diffuse large B-cell lymphoma: a therapeutic dilemma. Ann Hematol. 90:539–546. 2011.
19	Jacobson DM: Relative pupil-sparing third nerve palsy: etiology and clinical variables predictive of a mass. Neurology. 56:797–798. 2001.
20	Sato H, Hashimoto T, Yoneda S, Hirabayashi K, Oguchi K and Higuchi K: Lymphoma as a cause of isolated oculomotor nerve palsy. J Clin Neurosci. 18:1256–1258. 2011.